Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QUEEN-APPLE: QL1706 + anlotinib + nab-paclitaxel in first-line advanced triple-negative breast cancer
ChiCTR2600122562Phase 2Not yet recruiting
- Sponsor
- Affiliated Cancer Hospital of Nanjing Medical University
- Start
- Apr 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of QL1706 in breast cancer, sponsored by Affiliated Cancer Hospital of Nanjing Medical University. Primary endpoints: Progression-Free Survival (PFS) and Safety Outcomes. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
QL1706
03
Conditions
breast cancer
Beyond the preview
Go deeper on ChiCTR2600122562.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600122562.